Market Place
Sourcing Support
Spruce Biosciences Reports Q3 2024 Financial Results & Updates
11 Nov 2024 //
BUSINESSWIRE
Spruce Biosciences Participate at Guggenheim Healthcare Conference
28 Oct 2024 //
BUSINESSWIRE
Spruce Biosciences to Attend H.C. Wainwright Global Investment Conference
03 Sep 2024 //
BUSINESSWIRE
Spruce Biosciences Reports Q2 2024 Results And Corporate Updates
12 Aug 2024 //
BUSINESSWIRE
Spruce Biosciences Recognized as a Bay Area Best Place to Work
06 Jun 2024 //
BUSINESSWIRE
Spruce, HMNC: Partner For Major Depressive Disorder Treatment Development
04 Jun 2024 //
BUSINESSWIRE
Spruce`s Tildacerfont PCOS Phase 2 POWER Results At ENDO 2024
03 Jun 2024 //
BUSINESSWIRE
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
23 May 2024 //
BUSINESSWIRE
Spruce Bio Presents At Endocrine Society 2024
22 May 2024 //
BUSINESSWIRE
Spruce Biosciences Reports Q1 2024 Results, Corporate Updates
13 May 2024 //
BUSINESSWIRE
Spruce Biosciences to Participate in May Investor Conferences
01 May 2024 //
BUSINESSWIRE
Spruce Bio Additional Poster at PES 2024 Annual Meeting
30 Apr 2024 //
BUSINESSWIRE
Spruce Bio Pediatric Endocrine Society 2024 Poster
22 Apr 2024 //
BUSINESSWIRE
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
14 Mar 2024 //
FIERCE BIOTECH
Spruce Biosciences Announces Topline Results from CAHmelia-203
13 Mar 2024 //
BUSINESSWIRE
Spruce Reports Full Year 2023 Financial Results and Provides Corporate Updates
13 Mar 2024 //
BUSINESSWIRE
Spruce Biosciences to Present at the Oppenheimer 34th Annual Conference
30 Jan 2024 //
BUSINESSWIRE
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study
22 Jan 2024 //
BUSINESSWIRE
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203
05 Jan 2024 //
BUSINESSWIRE
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
04 Jan 2024 //
BUSINESSWIRE
US Patent Trial and Appeal Board to reconsider Spruce patents around treatment
06 Dec 2023 //
ENDPTS
Spruce Biosciences Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
02 Nov 2023 //
BUSINESSWIRE
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study
18 Oct 2023 //
BUSINESSWIRE
Spruce Biosciences Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
BUSINESSWIRE
Spruce Bio Announces Acceptance of Abstract for Presentation at ENDO 2023
12 Jun 2023 //
BUSINESSWIRE
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
25 May 2023 //
BUSINESSWIRE
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
24 May 2023 //
BUSINESSWIRE
Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala
22 May 2023 //
BUSINESSWIRE
Spruce Biosciences Reports 1Q 2023 FYR Results and Provides Corporate Updates
15 May 2023 //
BUSINESSWIRE
Spruce to Present Findings on Retrospective Analysis of Completion Rates
04 May 2023 //
BUSINESSWIRE
Spruce Biosciences Reports Full Year 2022 Financial Results
16 Mar 2023 //
BUSINESSWIRE
Spruce to Participate in the Oppenheimer 33rd Annual Healthcare Conference
28 Feb 2023 //
BUSINESSWIRE
Spruce Biosciences Announces $53.6 Million Private Placement Financing
09 Feb 2023 //
BUSINESSWIRE
Spruce to Participate in the SVB Securities Global Biopharma Conference
01 Feb 2023 //
BUSINESSWIRE
Spruce Provides Program Updates and Outlines Anticipated Milestones for 2023
09 Jan 2023 //
BUSINESSWIRE
Spruce and Kaken Announce Partnership to DevelopTildacerfont for CAH in Japan
05 Jan 2023 //
BUSINESSWIRE
Spruce Biosciences Reports 3Q 2022 Financial Results and Provides Updates
10 Nov 2022 //
BUSINESSWIRE
Spruce Biosciences to Participate in November Investor Conferences
26 Oct 2022 //
BUSINESSWIRE
Spruce to Participate in the H.C. Wainwright 24th Annual Global Conference
30 Aug 2022 //
BUSINESSWIRE
Spruce Biosciences Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
Spruce Biosciences to Participate in June Investor Conferences
01 Jun 2022 //
BUSINESSWIRE
Spruce Bio Announces Acceptance of Abstract for Presentation at ENDO 2022
31 May 2022 //
BUSINESSWIRE
Spruce Biosciences Reports First Quarter 2022 Financial Results
11 May 2022 //
BUSINESSWIRE
Spruce Biosciences to Participate in May Investor Conferences
03 May 2022 //
BUSINESSWIRE
Spruce Bio Appoints Libbie Mansell as Chief Regulatory and Quality Officer
11 Apr 2022 //
BUSINESSWIRE
Spruce Bio Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
14 Mar 2022 //
BUSINESSWIRE
Spruce Bio Reports Q4 and FY 2021 Financial Results; Provides Corporate Updates
14 Mar 2022 //
BUSINESSWIRE
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Conference
03 Feb 2022 //
BUSINESSWIRE
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
24 Jan 2022 //
BUSINESSWIRE
Spruce Biosciences Appoints Javier Szwarcberg as CEO
05 Jan 2022 //
BUSINESSWIRE
Spruce Biosciences to Participate in Piper Sandler Healthcare Conference
18 Nov 2021 //
BUSINESSWIRE
Spruce Biosciences Appoints Mike Grey as Interim CEO
15 Nov 2021 //
BUSINESSWIRE
Spruce Bio Reports Q3 2021 Financial Results and Provides Corporate Updates
15 Nov 2021 //
BUSINESSWIRE
Spruce Biosciences to Participate in September Investor Conferences
07 Sep 2021 //
BUSINESSWIRE
Spruce Announces Pediatric Classic CAH Program Details During Virtual R&D Day
25 Aug 2021 //
BUSINESSWIRE
Spruce Biosciences Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
BUSINESSWIRE
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont
21 Jun 2021 //
BUSINESSWIRE
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults
24 May 2021 //
BUSINESSWIRE
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults
24 May 2021 //
BUSINESSWIRE
